Trade BioNTech BNTX

Magbenta
 Bumili

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Mga pinakabagong balita

Ipakita nang marami
Frances Wang 2025 Apr 27, 16:00

ETFs That Outperform the S&P 500: ARKK, VGT, IWF, XBI

ETFs
Frances Wang 2025 Apr 27, 16:00

Forex Market Today: Analyzing Seasonal Patterns in Forex Market Trends

Forex
Frances Wang 2025 Apr 27, 16:00

Dow Jones today: Major Indexes Rise as Trump Signals Softer Trade Stance

Stocks
Tommy Yap 2025 Apr 27, 16:00

Morning Note: Gold Dips on Dollar Strength, ECB Eyes Rate Cut, Japan Denies FX Pressure

Morning Note Commodities Forex
Tommy Yap 2025 Apr 26, 21:00

Week Ahead: Canada Election and U.S. NFP in Focus

Forex Indices
Frances Wang 2025 Apr 24, 16:00

How will tariffs affect forex: EUR/USD pair weakens amid trade uncertainty

Forex
Frances Wang 2025 Apr 24, 16:00

Exchange Traded Funds News: Tech-Focused ETFs Gain Traction Amid AI Boom

ETFs
Tommy Yap 2025 Apr 24, 16:00

Morning Note: US-China Trade Deadlock; Nvidia's AI Leap; Canada Votes

Morning Note CAD Forex

Info

Spread

1.0992

Spread (%)

1.0371 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagbubukas

Lunes

13:31 - 19:59

Martes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Biyernes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

28976943104

Natitirang Pagbabahagi

240392992

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

2022-06-17

Araw ng Pag-alis ng Karapatan sa Dividend

2022-06-02

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-3.14

Alamin ang Higit Pa Tungkol sa Instrumentong ito

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Mga kaugnay na instrumento

Asset
Magbenta
Bumili
Change (%)

Mag-trade Ngayon

Mag-trade Ngayon

Mag-trade Ngayon

Mag-trade Ngayon
view_all_instruments

latest_education_articles

Ipakita nang marami
Trustpilot